Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Michael S. Lawrence"'
Autor:
Satoshi Yoda, Wafa Malik, Adam Langenbucher, Justin F. Gainor, Sai-Hong Ignatius Ou, Kylie Prutisto-Chang, Ramin Sakhtemani, Jennifer L Peterson, Aaron N. Hata, Alexander Drilon, Andrew Do, Jessica J. Lin, Adam J. Schoenfeld, Viola W. Zhu, Ted William Johnson, Jochen K. Lennerz, Lecia V. Sequist, Noura J. Choudhury, Ibiayi Dagogo-Jack, Subba R. Digumarthy, Christina Falcon, Charlotte E. Lee, Alice T. Shaw, Michael S. Lawrence, Beow Y. Yeap, Jennifer S. Temel, Harper Hubbeling
Publikováno v:
Clin Cancer Res
Purpose: Current standard initial therapy for advanced, ROS proto-oncogene 1, receptor tyrosine kinase fusion (ROS1)-positive (ROS1+) non–small cell lung cancer (NSCLC) is crizotinib or entrectinib. Lorlatinib, a next-generation anaplastic lymphoma
Autor:
Richard B. Lanman, Aditya Bardia, Brittany A. Reeves, Jochen K. Lennerz, Becky Nagy, Kristen M. Shannon, Daniel A. Haber, Beverly Moy, Shyamala Maheswaran, Brian Chirn, Gad Getz, Andrzej Niemierko, Laura Spring, Mehmet Toner, A. John Iafrate, Jerry Younger, Seth A. Wander, Michael S. Lawrence, Taronish D. Dubash, Douglas S. Micalizzi, Lee Zou, Erica Blouch, Whijae Roh, Neelima Vidula, Steven J. Isakoff, Giuliana Malvarosa, Antoine Simoneau, Leif W. Ellisen, Dejan Juric
Publikováno v:
Clinical Cancer Research. 26:4852-4862
Purpose: Plasma genotyping may identify mutations in potentially “actionable” cancer genes, such as BRCA1/2, but their clinical significance is not well-defined. We evaluated the characteristics of somatically acquired BRCA1/2 mutations in patien
Autor:
Emily Chin, Cyril H. Benes, Sara Stevens, Subba R. Digumarthy, Ashish Saxena, Alice T. Shaw, Beow Y. Yeap, Rebecca J. Nagy, Christopher G. Azzoli, Hetal D. Marble, Jessica J. Lin, Justin F. Gainor, Adam Langenbucher, Kylie Prutisto-Chang, Andrew Do, Jochen K. Lennerz, Satoshi Yoda, Nathaniel A. Adams, Marguerite Rooney, Aaron N. Hata, Michael S. Lawrence, Audris Oh, Ibiayi Dagogo-Jack
Publikováno v:
Clin Cancer Res
Purpose: Most ALK-positive lung cancers will develop ALK-independent resistance after treatment with next-generation ALK inhibitors. MET amplification has been described in patients progressing on ALK inhibitors, but frequency of this event has not b
Autor:
Marcin Imielinski, Gad Getz, Michael S. Lawrence, Peter S. Hammerman, Matthew Meyerson, Bryan Hernandez, Petar Stojanov
Publikováno v:
Clinical Cancer Research. 18:PR1-PR1
In contrast to lung adenocarcinoma in which a driving and potentially targetable genetic aberration can be identified in excess of 50% of tumors, only 10% can be found in squamous cell lung cancer, the second most common type of lung cancer, none of